2014 UK National Lipoprotein Apheresis Conference
7th March 2014, 09:00-1600
Venue: Hilton Manchester Airport Hotel,
Manchester Airport, Outwood Lane, Manchester, M90 4WP
CPD accreditation: 5 CPD applied for
Agenda:
0920-0930 Welcome: Dr Handrean Soran
Session 1
0930-1010 Underestimation of the importance of LDL-cholesterol lowering in cardiovascular disease prevention in current practice. Professor Paul Durrington, Professor of Medicine, University of Manchester, UK.
1010-1050 Lipoprotein (a) as a cardiovascular risk factor: review of evidence and therapeutic options. Dr Dermot Neely, Consultant in Clinical Biochemistry and Metabolic Medicine, Royal Victoria Infirmary, Newcastle, UK.
1050-1120 Coffee and networking
Session 2
1120-1200 HoFH; is it just double trouble? The role of the LDL-receptor in lipid metabolism and implications for therapeutic options. Dr Michael France, Consultant Chemical Pathologist, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
1200-1240 Lipoprotein Apheresis: who and how should we treat? Dr Dev Datta, University Hospital Cardiff, Cardiff, UK.
1240-1350 Lunch
Session 3
1350-1430 Lomitapide as a therapeutic option for HoFH. Professor Claudia Stefanutti, Professor of Internal Medicine, Extracorporeal Therapeutic Techniques Unit – Lipid Clinic and Atherosclerosis Prevention Centre, Department of Molecular Medicine ‘Sapienza’ University of Rome, Italy
1430-1500 Future therapeutic options for patients with HoFH. Dr Handrean Soran, Consultant Physician and Endocrinologist, Central Manchester University Hospital, UK.
1500-1530 Managing HoFH in children; challenges and options. Dr Andrew Morris, Consultant Paediatrician, Central Manchester University Hospitals NHS Foundation Trust.
1530-1600 Case discussions.
HoFH in children; pheresis as a therapeutic option.
1600 Close
Sponsors
Aegereon, AMGEN, AstraZeneca, Link Medical, Sanofi.
Please download invite below:
Endodiabesity 